{Reference Type}: Journal Article
{Title}: Efficacy and Safety of Rivaroxaban Versus Enoxaparin in Prevention of Recurrence of Venous Thrombo-Embolism Events in Cancer Patients: A Meta-Analysis.
{Author}: Awan AR;Ahmad A;Daniyal M;Khan MMH;Saeed SJ;Siddiqui MB;Hakeem S;Shahab A;Ali SH;Siddiqi AK;
{Journal}: Clin Appl Thromb Hemost
{Volume}: 30
{Issue}: 0
{Year}: 2024 Jan-Dec
{Factor}: 3.512
{DOI}: 10.1177/10760296241261364
{Abstract}: <B>OBJECTIVE: </B>To examine the effectiveness of rivaroxaban compared to enoxaparin in patients diagnosed with cancer and venous thromboembolism.<BR><B>METHODS: </B>A search of Pub Med, Scopus, and Google Scholar, from inception through April 2023 was conducted. Articles comparing rivaroxaban with enoxaparin in patients with cancer and VTE/PE/DVT were included. Review Manager Version 5.2 was utilised for the analysis of the following outcomes; VTE, PE, DVT, major bleeding, and mortality.<BR><B>RESULTS: </B>A total of 8 articles and 2276 patients were included in the final analysis. Pooled analysis showed that rivaroxaban had a statistically insignificant reduced association with VTE occurrence (RR:0.83, 95% CI:0.58-1.18, P:0.3) as well as a statically insignificant reduction in major bleeding (RR:0.79, 95% CI:0.53-1.18, P:0.25). Analysis showcased that there was an insignificant reduction of mortality rivaroxaban as compared to enoxaparin (RR:0.74, 95% CI: 0.46-1.20, P:0.23).<BR><B>CONCLUSIONS: </B>Rivaroxaban can serve as a viable alternative to enoxaparin, with no appreciable drawbacks, for preventing and managing VTE in patients with malignancy.